# Sino-Biocan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sino-biocan

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.sinobiocan.com
- Total disclosed funding: $30M
- Latest round: Series B (Mar 4, 2024)
- Investors on record: 6

## About

Based in Beijing, China, and founded in 2013. Sino-Biocan operates as a biotechnology company, focusing on the screening, diagnosis, treatment, and health management of tumors, cardiovascular and cerebrovascular diseases, immune diseases, and geriatric diseases. It has acquired ISO9001 and ISO13485 quality management system certification and cooperated with 86 partners. In November 2021, the cell preparation tool production base was completed. As of 2022, the company has nearly 50 employees. In March 2024, Sino-Biocan raised approximately CNY 100 million in series B funding. The founder, Dongbing Wei, used to serve as the head of Meitianni. He has experience in equipment and consumables.

The company's products can be categorized into automatic cell separation, automatic cell culture, automatic cell washing, and so on. In addition, it also provides users with tumor early screening services such as tumor antigen detection, circulating tumor cells, and DNA detection. Its products are widely used in the fields of cell and genetic drug development, medical stem cell preparation and application, umbilical blood bank management, and cell storage. The business has covered Beijing, Hong Kong, and other places.

The company will use the series B funds to build a production system, enhance research and development capabilities and global registration capabilities, and expand the global market.

## Funding rounds

- Series B, Mar 4, 2024, $14M — Sinovation Ventures, Grand Flight Investment, Neovision Capital, Dalton Venture, Jinjue Investment, Qikun Fund
- Series A, Jul 15, 2022 — Neovision Capital
- Series A, Mar 14, 2022, $16M — Sinovation Ventures, Grand Flight Investment
- Angel, Sep 22, 2021 — Sinovation Ventures

## Investors

- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Angel, Series A, Series B
- Grand Flight Investment (https://capitalatlas.ai/funds/grand-flight-investment) — Series A, Series B
- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series A, Series B
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series B
- Jinjue Investment (https://capitalatlas.ai/funds/jinjue-investment) — Series B
- Qikun Fund — Series B